Media headlines about Cellular Biomedicine Group (NASDAQ:CBMG) have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Cellular Biomedicine Group earned a news sentiment score of 0.22 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 44.1770072484275 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Shares of Cellular Biomedicine Group (NASDAQ:CBMG) traded up $0.45 during mid-day trading on Tuesday, reaching $11.00. 52,400 shares of the company’s stock traded hands, compared to its average volume of 33,644. Cellular Biomedicine Group has a 52 week low of $5.05 and a 52 week high of $13.80.
Separately, Maxim Group set a $18.00 price objective on shares of Cellular Biomedicine Group and gave the stock a “buy” rating in a report on Tuesday, August 29th.
Cellular Biomedicine Group Company Profile
Cellular Biomedicine Group, Inc (CBMG) is a biomedicine company. The Company is engaged in the development of treatments for cancerous and degenerative diseases utilizing cell-based technologies. The Company operates in Biomedicine Cell Therapy segment. The Company’s technology includes platforms, such as Immune Cell therapy for treatment of broad range of cancers using Vaccine, T Cells Receptor (TCR) clonality analysis technology and T Central Memory Cell (Tcm) preparation methodologies, Chimeric Antigen Receptor T cell (CAR-T), and human adipose-derived mesenchymal progenitor cells (haMPC) for treatment of joint and autoimmune diseases, with primary research and manufacturing facilities in China.
Receive News & Ratings for Cellular Biomedicine Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellular Biomedicine Group and related companies with MarketBeat.com's FREE daily email newsletter.